Mackenzi A Coker,
Speech Language Pathologist
Department:
MD-CHILD HEALTH RES INSTITUTE
Business Phone:
(352) 294-8754
Business Email:
mcoker@ufl.edu
About Mackenzi A Coker
Related Links:
Additional Positions:
Speech Language Pathologist
2015 – Current
·
Board Certifications
-
Certificate of Clinical CompetenceAmerican Speech Language and Hearing Association
Publications
Academic Articles
2025
Characterization of swallowing biomechanics and function in untreated infants with spinal muscular atrophy: A natural history dataset.
Journal of neuromuscular diseases.
12(1)
[DOI] 10.1177/22143602241308762.
[PMID] 39973456.
2024
Longitudinal changes of swallowing safety and efficiency in infants with spinal muscular atrophy who received disease modifying therapies
Pediatric Pulmonology.
[DOI] 10.1002/ppul.26919.
2024
Perspectives of the Friedreich ataxia community on gene therapy clinical trials.
Molecular therapy. Methods & clinical development.
32(1)
[DOI] 10.1016/j.omtm.2023.101179.
[PMID] 38261944.
Presentations
2024-11-13
Fiberoptic Endoscopic Evaluation of Swallowing is Feasible and Shows High Prevalence of Dysphagia in Patients with Friedreich’s Ataxia
International
/
Invited.
Poster.
London, UK
2025-05-01
Respiratory Function Correlates with Swallowing Related Quality of Life Measures in Patients with Friedreich’s Ataxia
National
/
Other.
Poster.
San Francisco, CA
2024-02-01
Gene Therapy-Treated Infants with Spinal Muscular Atrophy Exhibit Preserved Respiratory Strength but Reduced Coordination
National
/
Other.
Poster.
Boston, MA
2023-02-01
Respiratory Motor Control in Infants with Spinal Muscular Atrophy
Regional
/
Other.
Symposium.
University of Florida
2022-11-01
Reliability of Visual Perceptual Pharyngeal Residue Ratings on FEES Using a 100mm Visual Analogue Scale
Regional
/
Refereed.
Poster.
2022-11-01
The Opinion of Friedreich’s Ataxia Patients Towards Gene Therapy Trials
National
/
Invited.
Poster.
Dallas, TX
2022-11-01
Mitochondrial Dysfunction Measured by Cardiopulmonary Exercise Testing in Friedreich’s Ataxia
National
/
Invited.
Poster.
Dallas, TX
Grants
Oct 2022
ACTIVE
A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Ambulatory and Non-Ambulatory Participants with Spinal Muscular Atrophy with Open-Label Extension (RESILIENT)
Role: Other
Funding: BIOHAVEN PHARMACEUTICALS
Education
M.S. Speech Language Pathology
2013-2015
·
Florida Atlantic University
B.A. Communication Sciences and Disorders
2007-2011
·
University of South Florida
Contact Details
Phones:
- Business:
- (352) 294-8754
Emails:
- Business:
- mcoker@ufl.edu
Addresses:
- Business Mailing:
-
2004 MOWRY RD # 2256
GAINESVILLE FL 32610